• Transparency of Stakeholder Communications for Marketing and Advertising of Opioids Initiatives
• Restricting the Marketing and Advertising of Opioids
• What we heard: Defining vulnerable populations
• What we heard: Agile regulations for advanced therapeutic products and clinical trials
• Expert Advisory Group on Marketing of Opioids